Apotex Inc.

Stuart P Green

Yajun Zhao

Prabhudas Bodhuri

Mohammed Abdul Raheem

Minh T N Nguyen

Eduardo Gustavo Cammisa

Fabio E S Souza

Allan W Rey

Avedis Karadeolian

Alexander J Stirk

Siva Ramarao Kakani

Fan Wang

Cameron L McPhail

Alfredo Paul Ceccarelli

Jenny L Gerster

Melanie R A Green

Michael R Emmett

Mohamed Ibrahim Zaki

Fatemeh Mohammadpourmir

The present invention provides novel crystalline forms of zuclomiphene citrate. Specific crystalline forms provided by the present invention include zuclomiphene citrate Forms APO-I, APO-II, APO-III, and APO-IV. Also provided are pharmaceutical compositions including the zuclomiphene citrate crystalline forms, processes for the preparation thereof and the use of these forms in the treatment of a disorder selected from the group including osteoporosis, bone fractures, loss of bone mineral density (BMD) and hot flashes in a subject suffering therefrom.

Crystalline forms of zuclomiphene citrate

The present invention provides zuclomiphene salts, zuclomiphene binaphthyl hydrogen phosphate salt (1-A)&#xb7;(BPA) and zuclomiphene oxalate salt (1-A)&#xb7;(OXL), crystalline forms thereof and processes for the preparation thereof.

Zuclomiphene salts and crystalline forms thereof

The present invention provides a novel crystalline form of Valbenazine dibesylate, Valbenazine dibesylate Form APO-I, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of hyperkinetic disorders, including tardive dyskinesia.

Crystalline form of Valbenazine dibesylate

The present invention provides processes for the preparation of Tezacaftor, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (3), and its conversion to Tezacaftor (1). 

Processes for the preparation of Tezacaftor and intermediates thereof

The present invention provides processes for the preparation of Edoxaban (1) and salts thereof, as well as intermediates thereof. In particular, intermediate compounds and/or salts of the Formulae (3), (4), (6-A), (7-A), (8-A), (9-A) and (10-AS) are provided.

Processes for the preparation of edoxaban and intermediates thereof

Solid and crystalline forms of tofacitinib hydrochloride and tofacitinib hydrobromide, processes for the preparation thereof and processes for the use thereof in preparing tofacitinib citrate are provided.

Solid forms of tofacitinib salts

Growing community of inventors

Mount Pleasant, Canada

Stuart P Green